| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $5.4M | -10.6% |
| SG&A Expense | $8.7M | +1.9% |
| Net Income | -$14.1M | +3.3% |
| EPS (Basic) | -$0.87 | +24.3% |
| EPS (Diluted) | -$0.87 | +24.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Accounts Receivable | $51K | -60.4% |
| Total Assets | $3.9M | -50.0% |
| Current Liabilities | $3.2M | +6.6% |
| Total Liabilities | $3.2M | +6.6% |
| Stockholders' Equity | $615K | -86.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$10.4M | -5.9% |
| Financing Cash Flow | $6.6M | -19.0% |